Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD2O0L)

Drug Name

UX-001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hereditary inclusion body myositis	4A41.2	Phase 3	[1]
Myopathy	8C7Y	Phase 2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Influenza Neuraminidase (Influ NA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[4]
Zanamivir	DMFMBZ4	Influenza	1E30-1E32	Approved	[4]
Peramivir	DMNXY5K	Influenza virus infection	1E30-1E32	Approved	[5]
CS-8958	DM4CSDH	Influenza virus infection	1E30-1E32	Phase 3	[5]
DAS-181	DM0Y8JP	Influenza virus infection	1E30-1E32	Phase 2	[6]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[3]
GS-3435	DMV7JC6	Influenza virus infection	1E30-1E32	Terminated	[7]
BCX-140	DMBJERO	Influenza virus infection	1E30-1E32	Terminated	[8]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[3]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cytidine-5'-Diphosphate	DMA5FGS	Discovery agent	N.A.	Investigative	[3]
Cytidine-5'-Monophosphate	DM6PAXD	Discovery agent	N.A.	Investigative	[9]
Cmp-2-Keto-3-Deoxy-Octulosonic Acid	DMM9K5S	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)	TTQ8J1V	KDSB_ECOLI	Inhibitor	[3]
Influenza Neuraminidase (Influ NA)	TT50QJ3	NRAM_I33A0	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01830972) An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid (ER Tablets + IR Capsules) in Patients With GNE Myopathy. U.S. National Institutes of Health.
3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
5	Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
6	Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
7	US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
8	CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.
9	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.